Compare NOVT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOVT | GRFS |
|---|---|---|
| Founded | 1968 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.4B |
| IPO Year | 1999 | N/A |
| Metric | NOVT | GRFS |
|---|---|---|
| Price | $151.10 | $7.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $144.00 | $10.15 |
| AVG Volume (30 Days) | 440.6K | ★ 550.5K |
| Earning Date | 05-11-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $521,290,000.00 | N/A |
| Revenue This Year | $8.61 | $4.49 |
| Revenue Next Year | $6.57 | $6.42 |
| P/E Ratio | $304.18 | ★ $18.67 |
| Revenue Growth | ★ 35.49 | N/A |
| 52 Week Low | $98.27 | $7.26 |
| 52 Week High | $171.85 | $11.14 |
| Indicator | NOVT | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 41.33 |
| Support Level | $147.12 | $7.38 |
| Resistance Level | $168.71 | $8.88 |
| Average True Range (ATR) | 8.69 | 0.17 |
| MACD | -2.15 | 0.01 |
| Stochastic Oscillator | 8.18 | 24.69 |
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.